MXPA05011644A - Subexpresion de claudinas como marcadores de metastasis de tumor. - Google Patents

Subexpresion de claudinas como marcadores de metastasis de tumor.

Info

Publication number
MXPA05011644A
MXPA05011644A MXPA05011644A MXPA05011644A MXPA05011644A MX PA05011644 A MXPA05011644 A MX PA05011644A MX PA05011644 A MXPA05011644 A MX PA05011644A MX PA05011644 A MXPA05011644 A MX PA05011644A MX PA05011644 A MXPA05011644 A MX PA05011644A
Authority
MX
Mexico
Prior art keywords
claudin
cell
claudinsacoe
underexpression
markers
Prior art date
Application number
MXPA05011644A
Other languages
English (en)
Spanish (es)
Inventor
Kunyuan Cui
Original Assignee
Nastech Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nastech Pharm Co filed Critical Nastech Pharm Co
Publication of MXPA05011644A publication Critical patent/MXPA05011644A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MXPA05011644A 2003-04-30 2004-04-30 Subexpresion de claudinas como marcadores de metastasis de tumor. MXPA05011644A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46690503P 2003-04-30 2003-04-30
PCT/US2004/013436 WO2004098647A2 (en) 2003-04-30 2004-04-30 Claudins’ underexpression as markers of tumor metastasis

Publications (1)

Publication Number Publication Date
MXPA05011644A true MXPA05011644A (es) 2005-12-15

Family

ID=33434995

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05011644A MXPA05011644A (es) 2003-04-30 2004-04-30 Subexpresion de claudinas como marcadores de metastasis de tumor.

Country Status (8)

Country Link
US (1) US20040253211A1 (cg-RX-API-DMAC7.html)
EP (1) EP1620732A2 (cg-RX-API-DMAC7.html)
JP (1) JP2006525351A (cg-RX-API-DMAC7.html)
CN (1) CN100575955C (cg-RX-API-DMAC7.html)
CA (1) CA2523870A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA05011644A (cg-RX-API-DMAC7.html)
NO (1) NO20055449L (cg-RX-API-DMAC7.html)
WO (1) WO2004098647A2 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CA2672581A1 (en) * 2006-12-14 2008-06-19 Forerunner Pharma Research Co., Ltd. Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same
WO2008114733A1 (ja) 2007-03-16 2008-09-25 Kyowa Hakko Kirin Co., Ltd. 抗Claudin-4抗体
EP2404936A1 (en) * 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
KR101741898B1 (ko) 2015-05-27 2017-06-01 울산대학교 산학협력단 Claudin 7을 포함하는 방사선 반응성 위암 진단용 바이오마커 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554388A (en) * 1989-02-25 1996-09-10 Danbiosyst Uk Limited Systemic drug delivery compositions comprising a polycationi substance
US5744166A (en) * 1989-02-25 1998-04-28 Danbiosyst Uk Limited Drug delivery compositions
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
GB9310412D0 (en) * 1993-05-20 1993-07-07 Danbiosyst Uk Nasal nicotine system
GB9412394D0 (en) * 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
GB9419979D0 (en) * 1994-10-04 1994-11-16 Medeva Holdings Bv Vaccine compositions
GB9522351D0 (en) * 1995-11-01 1996-01-03 Medeva Holdings Bv Vaccine compositions
GB9525083D0 (en) * 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
US5976800A (en) * 1996-06-28 1999-11-02 The Regents Of The University Of California Enhancement of cancer cell death
WO1999027905A1 (en) * 1997-12-02 1999-06-10 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Compositions for nasal administration
GB9726916D0 (en) * 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
US6248864B1 (en) * 1997-12-31 2001-06-19 Adherex Technologies, Inc. Compounds and methods and modulating tissue permeability
AU2001253140A1 (en) * 2000-04-03 2001-10-15 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Tumor markers in ovarian cancer
CN1234727C (zh) * 2000-06-01 2006-01-04 北京双鹭药业股份有限公司 人胸腺素α原基因突变体合成、表达及应用
WO2003069307A2 (en) * 2002-02-14 2003-08-21 The Johns Hopkins University School Of Medicine Claudins, markers for diagnosis, prognosis and therapy of breast, bone, brain cancer

Also Published As

Publication number Publication date
NO20055449D0 (no) 2005-11-17
CN1816745A (zh) 2006-08-09
CA2523870A1 (en) 2004-11-18
US20040253211A1 (en) 2004-12-16
WO2004098647A3 (en) 2005-03-03
CN100575955C (zh) 2009-12-30
WO2004098647A2 (en) 2004-11-18
EP1620732A2 (en) 2006-02-01
NO20055449L (no) 2006-01-26
JP2006525351A (ja) 2006-11-09

Similar Documents

Publication Publication Date Title
TW200728465A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
MXPA02000192A (es) Composiciones y metodos para la terapia y diagnostico de cancer de pulmon.
WO2001072295A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2004052276A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
RU2009138327A (ru) Композиции и способы направленного устранения мутационного ускользания в направленной терапии рака
WO2001051633A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
DE60126592D1 (de) Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs
WO2001073032A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2002016413A3 (en) Cripto tumour polypeptide
PT1157041E (pt) Anticorpos para terapia e diagnostico de cancro
UA90082C2 (ru) Выделенное моноклональное антитело человека, которое специфически связывается с cd25 человека и ингибирует связывание il-2 с cd25
WO2002004514A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
EP1272636B8 (en) A gene differentially expressed in breast and bladder cancer and encoded polypeptides
WO2002092001A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2003037267A8 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2004098647A3 (en) Claudins’ underexpression as markers of tumor metastasis
WO2001077168A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2005051990A3 (en) Polynucleotides overexpressed in breast cancer cells, compositions and methods for the therapy and diagnosis of breast cancer
WO2001090152A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2003086175A8 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2002000174A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2020176461A3 (en) Methods and compositions for treating neuroendocrine prostate cancer
WO2001094409A3 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
WO2000004918A3 (de) Mittel zur immuntherapie von tumorerkrankungen
WO2002047534A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer

Legal Events

Date Code Title Description
FA Abandonment or withdrawal